Incidence of vancomycin-resistant enterococci (VRE) infection in high-risk febrile neutropenic patients colonized with VRE
- 558 Downloads
This study seeks to determine the incidence of vancomycin-resistant enterococci (VRE) infection in high-risk neutropenic fever patients colonized with VRE and to determine patient characteristics associated with VRE infection.
We conducted a retrospective, single-center, unmatched case-control study. Fifty-three VRE-colonized, high-risk patients with neutropenic fever were identified between January 2006 and February 2009. The two most common diagnoses/conditions included acute myeloid leukemia and hematopoietic stem cell transplantation. Data collected included days of neutropenia, days of fever, demographic data, culture results, and antimicrobial therapy.
Twenty of the 53 patients (38%) with VRE colonization developed a VRE infection. The most common VRE infections were bacteremias (26%). The presence of neutropenia lasting longer than 7 days was associated with the development of VRE infection in this high-risk population colonized with VRE. The timeframe to develop VRE infection varied from 1 day to 2 weeks.
For patients colonized with VRE, approximately 38% of high-risk neutropenic patients developed a VRE infection. This is the first study to specifically evaluate the incidence of VRE infections in febrile neutropenic patients colonized with VRE. Future research into the use and efficacy of empiric VRE coverage is needed.
KeywordsVancomycin-resistant enterococci (VRE) Febrile neutropenia Daptomycin Linezolid
hematopoietic stem cell transplantation
blood stream infection
absolute neutrophil count
- 2.National Comprehensive Cancer Network. 2008 Prevention and treatment of cancer-related infections. [http://www.nccn.org/professionals/physician_gls/PDF/infections.pdf] Accessed 12/11/08
- 16.Eys A, Rapoport BL, Anderson R (2004) Febrile neutropenia: a prospective study to validate the Multinational Associatation of Supportive Care of Cancer (MASCC) risk-index score. Support Care Cancer 12:555–560Google Scholar
- 18.Rostein C, Mandell LA, Goldberg N (1997) Fluoroquinolone prophylaxis for profoundly neutropenic cancer patients: a meta-analysis. Curr Opin Oncol 4(Suppl 2):S2–S7Google Scholar